Bristol-Myers Squibb (BMY) Partners with Anthropic

Bristol-Myers Squibb Company (NYSE:BMY) is one of the 12 Most Undervalued Stocks to Invest In.

On May 20, 2026, Bristol-Myers Squibb Company (NYSE:BMY) announced a strategic agreement with Anthropic to deploy Claude across its research, clinical development, manufacturing, commercial, and corporate functions. Bristol Myers Squibb said the collaboration moves its AI use beyond conversational tools and toward agentic capabilities embedded in daily workflows and systems. The company plans to deploy Claude broadly across the business, giving more than 30,000 employees access to advanced reasoning and agentic capabilities.

On May 8, 2026, Bristol Myers Squibb announced that the European Commission approved Sotyktu, or deucravacitinib, alone or in combination with methotrexate, for adults with active psoriatic arthritis who had an inadequate response or intolerance to a prior disease-modifying antirheumatic therapy. The company said Sotyktu is the first TYK2 inhibitor approved for active PsA in the European Union. The approval was based on the POETYK PsA-1 and POETYK PsA-2 Phase 3 trials, where Sotyktu showed significant improvement in disease activity as measured by the American College of Rheumatology 20 and Minimal Disease Activity.

Bristol-Myers Squibb (BMY) Partners with Anthropic

Last month, Bristol Myers reported Q1 adjusted EPS of $1.58, ahead of the consensus estimate of $1.42. Revenue totaled $11.49B, above the consensus estimate of $10.92B. Board Chair and CEO Christopher Boerner said the company was off to a “good start in 2026,” citing momentum across its Growth Portfolio and disciplined execution. Boerner also pointed to multiple pivotal data readouts and pipeline opportunities ahead.

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1